Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-elicited SARS-CoV-2 Immune Responses.
Saved in:
| Title: | Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-elicited SARS-CoV-2 Immune Responses. |
|---|---|
| Authors: | Smith D; University of California San Diego; La Jolla, CA, USA., Weir IR; Center for Biostatistics in AIDS Research in the Department of Biostatistics Harvard T.H. Chan School of Public Health; Boston, MA, USA., Ramirez S; University of California San Diego; La Jolla, CA, USA.; Center for Vaccine Innovation, La Jolla Institute for Immunology; La Jolla, CA, USA., Coelho CH; Center for Vaccine Research and Pandemic Preparedness, Department of Microbiology, and Precision Immunology Institute, Icahn School of Medicine at Mount Sinai; New York, NY, USA., Manne-Goehler J; Brigham and Women's Hospital, Harvard Medical School; Boston, MA, USA., Aziz M; Rush University Medical Center; Chicago, IL, USA., Benson CA; University of California San Diego; La Jolla, CA, USA., Wu X; Center for Biostatistics in AIDS Research in the Department of Biostatistics Harvard T.H. Chan School of Public Health; Boston, MA, USA., Hyer R; Moderna, Inc., Cambridge, MA., Dhillon PK; DLH Corporation; Silver Spring, MD, USA., Faraji F; University of California San Diego; La Jolla, CA, USA.; Center for Vaccine Innovation, La Jolla Institute for Immunology; La Jolla, CA, USA., Bloom N; Center for Vaccine Innovation, La Jolla Institute for Immunology; La Jolla, CA, USA., Myers A; Center for Vaccine Innovation, La Jolla Institute for Immunology; La Jolla, CA, USA., Ramezani-Rad P; Center for Vaccine Innovation, La Jolla Institute for Immunology; La Jolla, CA, USA., Lopez PG; Center for Vaccine Innovation, La Jolla Institute for Immunology; La Jolla, CA, USA., Parikh UM; University of Pittsburgh, School of Medicine, Division of Infectious Diseases; Pittsburgh, Pennsylvania, USA., Heaps AL; University of Pittsburgh, School of Medicine, Division of Infectious Diseases; Pittsburgh, Pennsylvania, USA., Javan AC; National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda, MD, USA., Bender Ignacio RA; University of Washington; Seattle, WA, USA.; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center; Seattle, WA, USA., Li JZ; Brigham and Women's Hospital, Harvard Medical School; Boston, MA, USA., Greninger AL; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center; Seattle, WA, USA.; Department of Laboratory Medicine and Pathology, University of Washington Medical Center; Seattle, WA, USA., Daar ES; Lundquist Institute at Harbor-UCLA Medical Center; Torrance, CA, USA., Wohl DA; University of North Carolina at Chapel Hill; Chapel Hill, NC, USA., Crotty S; Center for Vaccine Innovation, La Jolla Institute for Immunology; La Jolla, CA, USA., Sieg SF; Case Western Reserve University School of Medicine; Cleveland, OH, USA.; University Hospitals of Cleveland; Cleveland, OH, USA., Chew KW; David Geffen School of Medicine at University of California, Los Angeles; Los Angeles, CA, USA. |
| Source: | The Journal of infectious diseases [J Infect Dis] 2026 Feb 17. Date of Electronic Publication: 2026 Feb 17. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
